Ubrolexin® - product information
Ubrolexin® intramammary suspension for lactating dairy cows
Each tube contains:
Cefalexin (as monohydrate): 200 mg
Kanamycin (as monosulphate): 100,000 I.U.
Treatment of clinical mastitis in lactating dairy cows for bacteria susceptible to the combination of cefalexin and kanamycin such as Staphylococcus aureus , Streptococcus dysgalactiae, Streptococcus uberis and Escherichia coli.
Treat the infected quarter(s) twice, leaving an interval of 24 hours between treatments.
The combination of cefalexin and kanamycin showed a bactericidal mode of action against Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis and Escherichia coli.
Minimum inhibitory concentration, checkerboard analysis, kill kinetic and post antibiotic effect data demonstrate an advantage of the combination by broadening the activity spectrum and by showing synergistic antibacterial activity: the effect of cefalexin is enhanced by kanamycin and vice versa.
Further, the combination produces a larger suppression of bacterial growth (post antibiotic effect) against all target mastitis pathogens compared with the individual compounds.
In vitro studies demonstrate that isolates of S. agalactiae and coagulase-negative staphylococci are susceptible to the combination of active substances.
Meat and offal: 10 days
Milk: 5 days
